SecBot SecBot
Biotech Drug Report Generated Jul 9, 2026

NX-3911

NRIX·Nurix Therapeutics, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Preclinical / IND-enabling, Phase 1 trial authorized (EU CTIS) but not yet recruiting
Time to market
Unknown, still in preclinical/IND-enabling stage with Phase 1 trial authorized but not recruiting; likely 5-7+ years from potential approval if successful
Why 2/10
NX-3911 has no hard, dated binary catalyst in the next ~12 months. The Phase 1 trial is authorized in the EU (CTIS2026-526014-87-00) but not yet recruiting. Even when Phase 1 data read out, this is a partnered program with Sanofi (not Nurix's lead asset), so the stock impact is indirect and diluted. NRIX's main value drivers are the bexobrutideg/Roche deal and its wholly-owned pipeline.
Actionable Insight NEUTRAL

NX-3911 is a minor, partnered pipeline component for NRIX. Investors should focus on the company's wholly-owned BTK degrader bexobrutideg (partnered with Roche, $700M upfront) and other pipeline catalysts for stock movement. NX-3911 specific news (Phase 1 initiation or early data) would likely drive only modest, indirect moves via milestone optics.

Price Chart

Loading chart...

Executive Summary

NX-3911 is an oral STAT6 degrader being developed by Nurix Therapeutics (NRIX) in collaboration with Sanofi for Type 2 inflammatory diseases (atopic dermatitis, asthma). Sanofi licensed the program in June 2025 for $15M upfront, with up to $465M in milestones. The drug is still in preclinical/IND-enabling stages; a Phase 1 EU trial is authorized but not recruiting. NX-3911 is a minor pipeline component for NRIX, which recently signed a transformative $700M upfront deal with Roche for its lead BTK degrader bexobrutideg. NX-3911 faces significant competition from Kymera's KT-621 (already in Phase 2b) and Recludix/Sanofi's REX-8756 (Phase 1). For NRIX investors, this drug is a long-dated, partnered option, not a near-term catalyst.

How It Works

NX-3911 is an oral (pill) drug that uses targeted protein degradation to destroy a protein called STAT6 inside cells. STAT6 is a key signaling molecule in allergic and inflammatory conditions like atopic dermatitis (eczema) and asthma. By degrading STAT6, the drug aims to shut down the inflammation-driving pathway at its source. This is a degrader approach (destroy the protein) rather than a traditional inhibitor (block the protein).

Trial Status

NX-3911 advanced into IND-enabling studies after Sanofi exercised a license extension option in June 2025. An EU-authorized Phase 1 trial (CTIS2026-526014-87-00, sponsored by Sanofi) was registered but recruitment has not yet started as of mid-2026. The drug is still described as "preclinical stage" in company materials from May/June 2026.

The Two-Sided Case

▲ Bull Case3
STAT6 is a validated, once-'undruggable' target in a large market (atopic dermatitis, asthma) with blockbuster potential, oral degrader approach may offer best-in-class profile.
Sanofi's exercise of the license option validates NX-3911 preclinically; Nurix retains right to opt into 50/50 U.S. profit share after clinical proof of concept, preserving upside.
Nurix's $1.24B pro-forma cash balance (post-Roche deal) removes dilutive financing risk; the Sanofi collaboration provides non-dilutive funding for NX-3911 development.
▼ Bear Case3
NX-3911 is years behind Kymera's KT-621, which completed Phase 1b with 98% STAT6 degradation, has FDA Fast Track, and is already in Phase 2b atopic dermatitis with enrollment completed, Phase 3 targeted by mid-2027.
As a partnered program with Sanofi, positive data benefits NRIX only indirectly through milestones and the opt-in right; Sanofi controls development timelines and could deprioritize.
Nurix's pipeline presentation as of mid-2026 still lists NX-3911 as 'preclinical stage', and the Phase 1 trial has not yet started recruiting, development is still very early and timelines are uncertain.

Upcoming Catalysts

  • Phase 1 trial initiation (EU CTIS trial CTIS2026-526014-87-00), recruitment start date unknown
  • Potential early Phase 1 data readout (no date announced)
  • Sanofi milestone payments triggered by development progress

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Nurix Therapeutics, Inc. PRESS-RELEASE NRIX ·Originating report

Sources · 11

Hover a chip for the title
1 ir.nurixtx.com2 fiercebiotech.com3 biospace.com4 synapse.patsnap.com5 ir.nurixtx.com6 ir.nurixtx.com7 ir.nurixtx.com8 labiotech.eu9 drughunter.com10 adisinsight.springer.com11 ctis.eu